# Coxsackie Virus A21 Administered Intravenously (IV) for Solid Tumour Cancers (PSX-X04)

> **NCT00636558** · PHASE1 · COMPLETED · sponsor: **Viralytics** · enrollment: 8 (actual)

## Conditions studied

- Melanoma
- Breast Cancer
- Prostate Cancer

## Interventions

- **DRUG:** CVA21

## Key facts

- **NCT ID:** NCT00636558
- **Lead sponsor:** Viralytics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-02-29
- **Primary completion:** 2012-01-12
- **Final completion:** 2012-01-12
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2019-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00636558

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00636558, "Coxsackie Virus A21 Administered Intravenously (IV) for Solid Tumour Cancers (PSX-X04)". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00636558. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*